WASHINGTON, D.C. – President and CEO of AdvaMed Scott Whitaker released the following statement: “Given recent allegations of price gouging in some parts of the country, it is important to be perfectly clear: “Our member companies’ No. 1 priority is saving lives and at no time in our history has that been more apparent than over the past month as they have dramatically ramped up production of the diagnostics and devices that are essential to identifying, treating and combatting COVID-19.
Press Release | April 2, 2020
Press Release | April 1, 2020
WASHINGTON, D.C. – The Advanced Medical Technology Association announced today that its member respiratory device companies have dramatically expanded the limits of their present production capacity in responding to the coronavirus outbreak, producing on average 2,000-3,000 ventilators per week, collectively, according to a recent survey of the seven member companies. In the coming weeks, company officials expect to ramp production to unprecedented levels, producing between an aggregated 5,000 and 7,000 ventilators per week in meeting the greatest needs across the nation. In 2019, when tallied together, these same companies were manufacturing approximately 700 ventilators per week for domestic distribution.
Press Release | March 31, 2020
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today released the following statements by Scott Whitaker, AdvaMed president and CEO, and Susan Van Meter, executive director of AdvaMedDx, regarding the medtech industry’s ongoing response to the coronavirus pandemic:
April 22, 2020 |
In response to the novel Coronavirus (COVID-19) outbreak, China NMPA (formerly the CFDA) issued over 70 emergency approvals of medical devices, diagnostic assays, protective supplies and... Read More
April 23, 2020 to April 24, 2020| Washington, DC
COVID-19 Update After much consideration and discussion, AdvaMed has made the decision to cancel the 13th Annual FDA/AdvaMed Medical Devices and Diagnostics Statistical Issues Conference scheduled... Read More
May 14, 2020 to May 15, 2020| Washington, DC
COVID-19 Update After much consideration and discussion, AdvaMed has made the decision to cancel the Advertising and Promotion of Medical Devices Conference scheduled for May 14-15, 2020 at the... Read More
May 19, 2020 to May 20, 2020| Los Angeles, CA
COVID-19 Update After much consideration and discussion, AdvaMed has made the decision to cancel The Digital MedTech Conference scheduled for May 19-20, 2020 at the Millenium Biltmore Hotel in Los... Read More
June 9, 2020 | Washington, DC
Hear from women CEOs, senior leaders and a member of congress on how they are shaping the future of our industry. Register now to receive early bird pricing while we finalize this exciting program.... Read More
AdvaMed CEO Scott Whitaker interviews with Fox Business on working with the White House, organizations like FEMA and the FDA and medtech companies to fight coronavirus.
Martinez, CA, USA – March 26, 2020 – Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA. Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical cases improved lung function and rapid reduction of drug-resistant bacterial pathogens occurred with Seraph 100...
HAYWARD, Calif.--RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* to treat all stages of cancer today announced it has received marketing clearance from the U.S. Food & Drug Administration (FDA) for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT) for its RefleXion™ X1 machine. “We are at the forefront of an enormous change in expanding the use of radiotherapy from a...
BOSTON and SYDNEY — 28 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan Medicine in Ann Arbor, Michigan. Michigan Medicine is one of five clinical study sites for the STEP-1 trial; the site is led by principal investigator Allison R. Schulman M.D., M.P.H., assistant professor of...
SAN JOSE, Calif., December 3, 2019 — Venclose Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease today announced it has closed a Series C funding led by Ally Bridge Group (ABG). ABG is a global life science-focused group with a successful investment record globally in supporting high-growth innovative life science companies. “Securing this financing further confirms continued investor confidence in Venclose’s...
Prime Employers for Women Medtronic and BD Discuss Inclusion and Diversity at the Prestigious MedTech Conference
Where Women Work
Prime employers for women BD and Medtronic both attended the prestigious MedTech Conference and addressed industry delegates. The conference saw more than 3,300 of the world’s top medical technology executives gather in Boston, USA, for educational programming, valuable networking and business development opportunities. Positioning corporate diversity and inclusion for success BD’s VP of Inclusion & Diversity Johnel Evans joined other executive leaders on a panel discussing positioning...
April 8, 2020 - 2:13pm
April 8, 2020 - 1:40pm
Evidation CEO, Deb Kilpatrick, shares her thoughts on the impact COVID-19 will have on the health care industry at-… https://t.co/6LDStUskNm